Aβ conformer selective anti-Aβ globulomer monoclonal antibodies

• US 9,951,125 B2
• Filed: 05/16/2016
• Issued: 04/24/2018
• Est. Priority Date: 11/30/2006
• Status: Active Grant

• Current Assignee: Abbvie Deutschland GmbH & Company KG (Abbvie Incorporated)
• Original Assignee: Abbvie Deutschland GmbH & Company KG (Abbvie Incorporated), Abbvie Incorporated
• Inventors: Barghorn, Stefan, Hillen, Heinz, Striebinger, Andreas R., Labkovsky, Boris, Ebert, Ulrich, Keller, Patrick
• Primary Examiner(s): Ballard, Kimberly
• Application Number:
  US15/155,739
• Publication Number:
  US 20160326238A1
• Time in Patent Office: 708 Days
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/10 characterized by their source of isolation or production
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 2800/2821 Alzheimer
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer'"'"'s Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.

Claims

1. An isolated antibody having a higher affinity to Aβ

(1-42) globulomer than to at least one amyloid beta protein selected from the group consisting of a) Aβ

(1-42) peptide present in cerebrospinal fluid (CSF) and b) Aβ

(1-40) peptide present in CSF, wherein the antibody comprises;

(i) the amino acid sequences of the Complementary Determining Region (CDR) 1, CDR2, and CDR3 of the heavy chain variable region (VH) of SEQ ID NO;

5 and the amino acid sequences of the CDR1, CDR2, and CDR3 of the light chain variable region (VL) of SEQ ID NO;

6, or

(ii) the amino acid sequences of the CDR1, CDR2, and CDR3 of the heavy chain variable region (VH) of SEQ ID NO;

7 and the amino acid sequences of the CDR1, CDR2, and CDR3 of the light chain variable region (VL) of SEQ ID NO;

8.

3. The isolated antibody of claim 1 or claim 2 wherein said antibody comprises:

(i) the amino acid sequence of the VH CDR1 of SEQ ID NO;

9, the amino acid sequence of the VH CDR2 of SEQ ID NO;

10, the amino acid sequence of the VH CDR3 of SEQ ID NO;

11, the amino acid sequence of the VL CDR1 of SEQ ID NO;

12, the amino acid sequence of the VL CDR2 of SEQ ID NO;

13, and the amino acid sequence of the VL CDR3 of SEQ ID NO;

14, or

(ii) the amino acid sequence of the VH CDR1 of SEQ ID NO;

15, the amino acid sequence of the VH CDR2 of SEQ ID NO;

16, the amino acid sequence of the VH CDR3 of SEQ ID NO;

17, the amino acid sequence of the VL CDR1 of SEQ ID NO;

18, the amino acid sequence of the VL CDR2 of SEQ ID NO;

19, and the amino acid sequence of the VL CDR3 of SEQ ID NO;

20.

4. The isolated antibody of claim 1 or claim 2, wherein the antibody is a monoclonal antibody.

5. The isolated antibody of claim 4, wherein the antibody is a recombinant antibody.

6. The isolated antibody of claim 1 or claim 2, wherein the antibody is humanized.

7. The isolated antibody of claim 1 or claim 2, wherein the VH of the antibody comprises the amino acid sequence of SEQ ID NO:

5 and the VL of the antibody comprises the amino acid sequence of SEQ ID NO;

6.

8. The isolated antibody of claim 7, wherein the antibody comprises a human IgG1 heavy chain constant region or a human IgG4 heavy chain constant region.

9. The isolated antibody of claim 7, wherein the antibody comprises a human kappa light chain constant region.

10. The isolated antibody of claim 1 or claim 2, wherein the VH of the antibody comprises the amino acid sequence of SEQ ID NO:

7 and the VL of the antibody comprises the amino acid sequence of SEQ ID NO;

8.

11. The isolated antibody of claim 10, wherein the antibody comprises a human IgG1 heavy chain constant region or a human IgG4 heavy chain constant region.

12. The isolated antibody of claim 10, wherein the antibody comprises a human kappa light chain constant region.

13. A composition comprising said antibody of claim 1 or said antibody of claim 2.

14. The composition of claim 13, wherein the composition is a pharmaceutical composition and further comprises a pharmaceutical acceptable carrier.

15. A vaccine comprising:

a) said antibody of claim 1 or said antibody of claim 2 and b) a pharmaceutically acceptable adjuvant.

16. A kit comprising:

a) said antibody of claim 1 or said antibody of claim 2 and b) a conjugate comprising an antibody attached to a signal-generating compound, wherein said antibody of said conjugate is different from said isolated antibody.

17. An isolated antibody produced by a method comprising culturing a host cell comprising a vector comprising an isolated nucleic acid molecule;

wherein the isolated nucleic acid molecule comprises at least one sequence selected from the group consisting of SEQ ID NO;

1, SEQ ID NO;

2, SEQ ID NO;

3 and SEQ ID NO;

4;

wherein the isolated nucleic acid molecule encodes the antibody of claim 1.

18. A method of identifying compounds suitable for active immunization of a patient predicted to develop Alzheimer'"'"'s Disease comprising the steps of:

a) exposing one or more compounds of interest to said antibody of claim 1 or said antibody of claim 2, for a time and under conditions sufficient for said one or more compounds to bind to said antibody of claim 1 or said antibody of claim 2; and

b) identifying those compounds which bind to said isolated antibody of 1 or said antibody of claim 2, said identified compounds to be used in active immunization in a patient predicated to develop Alzheimer'"'"'s Disease.

2. An isolated antibody having a higher affinity to Aβ

(1-42) globulomer than to at least one amyloid beta protein selected from the group consisting of a) Aβ

(1-42) peptide present in cerebrospinal fluid (CSF), and b) Aβ

(1-40) peptide present in CSF, wherein the antibody comprises;

(i) the amino acid sequences of the VH CDR1 VH CDR2 VH CDR3 VL CDR1 VL CDR2, and VL CDR3 of a monoclonal antibody (10F4) obtainable from a hybridoma designated by American Type Culture Collection (ATCC) deposit number PTA-7808, or

(ii) the amino acid sequences of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a monoclonal antibody (3C5) obtainable from a hybridoma designated by ATCC deposit number PTA-7406.

19. An isolated antibody produced by the hybridoma having ATCC deposit number PTA-7406 or PTA-7808.